TERN Company Profile and Key Details

Q: Who are the executives of TERN?

Dr. Mark Joseph VignolaChief Financial Officer & TreasurerDr. Jeffrey R. Jasper Ph.D.Senior Vice President & Head of ResearchDr. Kerry Russell M.D., Ph.D.Chief Medical Officer of MetabolicDr. Weidong Zhong Ph.D.Co-Founder & Executive OfficerMr. Senthil Vel SundaramChief Executive Officer & DirectorMs. Diana ChungSenior Vice President & Chief Devel. OfficerMr. Seokho Yoon Esq.Chief Operating Officer, Gen. Counsel & Sec.Dr. Erin Quirk M.D.Pres & Head of R&D

NASDAQ : TERN

Terns Pharmaceuticals

$52.95

-0.017-0.03%

At Close 4:00 PM

Not Actively Trading

69.79

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Terns Pharmaceuticals, Inc. (TERN) stock declined over -0.03%, trading at $52.95 on NASDAQ, down from the previous close of $52.97. The stock opened at $52.97, fluctuating between $52.95 and $52.97 in the recent session.

Stock Snapshot

52.967

Prev. Close

4.77B

Market Cap

52.95

Day Low

-51.407766990291265

P/E Ratio

-1.03

EPS (TTM)

-0.93

Cash Flow per Share

52.97

Open

90.08M

Number of Shares

52.97

Day High

79.51%

Free Float in %

3.53

Book Value

6.33M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 15, 2026	52.97	52.97	52.95	52.95	6.33M
May 04, 2026	52.97	52.98	52.94	52.95	6.34M
Apr 30, 2026	52.95	52.95	52.92	52.93	1.77M
Apr 29, 2026	52.95	52.96	52.92	52.92	1.76M
Apr 28, 2026	52.95	52.97	52.92	52.94	4.29M
Apr 27, 2026	52.89	52.96	52.89	52.95	4.13M
Apr 23, 2026	52.83	52.86	52.79	52.83	2.59M
Apr 22, 2026	52.83	52.85	52.78	52.84	2.69M
Apr 21, 2026	52.71	52.87	52.71	52.86	5.23M
Apr 20, 2026	52.66	52.74	52.65	52.74	4.08M
Apr 17, 2026	52.72	52.72	52.61	52.65	6.39M
Apr 16, 2026	52.73	52.75	52.66	52.69	4.77M
Apr 14, 2026	52.67	52.69	52.60	52.68	3.86M
Apr 13, 2026	52.70	52.75	52.60	52.61	6.74M
Apr 10, 2026	52.64	52.67	52.60	52.63	4.98M
Apr 09, 2026	52.65	52.67	52.56	52.56	11.82M
Apr 08, 2026	52.63	52.71	52.55	52.66	12.99M
Apr 07, 2026	52.73	52.74	52.42	52.62	28.8M
Apr 06, 2026	52.73	52.82	52.70	52.78	6.13M
Apr 02, 2026	52.76	52.77	52.65	52.72	10.85M

Contact Details

Foster City, CA 94404

United States

https://www.ternspharma.com 650 525 5535

About Company

Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.

Stock Peers

ARGX

-1.37-0.16%

argenx SE$876.25 REGN

-1.43-0.22%

Regeneron Pharmaceuticals, Inc.$663.09 UTHR

-11.49-2.10%

United Therapeutics Corporation$535.57 MDGL

-5.7-1.06%

Madrigal Pharmaceuticals, Inc.$531.00 VRTX

-5.14-1.06%

Vertex Pharmaceuticals Incorporated$480.25 KRYS

-2.37-0.65%

Krystal Biotech, Inc.$363.44 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-10.43-3.21%

Praxis Precision Medicines, Inc.$314.56 LGND

-6.99-2.21%

Ligand Pharmaceuticals Incorporated$309.25 ONC

5.26001+1.76%

BeOne Medicines AG$303.96

Frequently Asked Questions

What is the current Terns Pharmaceuticals, Inc. (TERN) stock price?

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) stock price is $52.95 in the last trading session. During the trading session, TERN stock reached the peak price of $52.97 while $52.95 was the lowest point it dropped to. The percentage change in TERN stock occurred in the recent session was -0.03% while the dollar amount for the price change in TERN stock was - $0.02.

TERN's industry and sector of operation?

The NASDAQ listed TERN is part of Biotechnology industry that operates in the broader Healthcare sector. Terns Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of TERN?

Dr. Mark Joseph Vignola
Chief Financial Officer & Treasurer
Dr. Jeffrey R. Jasper Ph.D.
Senior Vice President & Head of Research
Dr. Kerry Russell M.D., Ph.D.
Chief Medical Officer of Metabolic
Dr. Weidong Zhong Ph.D.
Co-Founder & Executive Officer
Mr. Senthil Vel Sundaram
Chief Executive Officer & Director
Ms. Diana Chung
Senior Vice President & Chief Devel. Officer
Mr. Seokho Yoon Esq.
Chief Operating Officer, Gen. Counsel & Sec.
Dr. Erin Quirk M.D.
Pres & Head of R&D

How TERN did perform over past 52-week?

TERN's closing price is 1,894.35% higher than its 52-week low of $2.66 where as its distance from 52-week high of $53.19 is -0.45%.

How many employees does TERN have?

Number of TERN employees currently stands at 59.

Link for TERN official website?

Official Website of TERN is: https://www.ternspharma.com

How do I contact TERN?

TERN could be contacted at phone 650 525 5535 and can also be accessed through its website. TERN operates from 1065 East Hillsdale Boulevard, Foster City, CA 94404, United States.

How many shares of TERN are traded daily?

TERN stock volume for the day was 6.33M shares. The average number of TERN shares traded daily for last 3 months was 5.92M.

What is the market cap of TERN currently?

The market value of TERN currently stands at $4.77B with its latest stock price at $52.95 and 90.08M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	59
Beta	-0.38
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	59
Beta	-0.38
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

TERN Company Profile and Key Details

Terns Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways